Is amoxapine an atypical antipsychotic? Positron-emission tomography investigation of its dopamine2 and serotonin2 occupancy

Biological Psychiatry

Volumn 45, Issue 9, 1999, Pages 1217-1220

  Kapur, Shitij ^a,b,c   Cho, Raymond ^a   Jones, Corey ^a   McKay, Gordon ^d   Zipursky, Robert B ^a,b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c ROTMAN RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Amoxapine; Atypical antipsychotics; Dopamine; Positron emission tomography; Serotonin

Indexed keywords

AMOXAPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; SEROTONIN 2 ANTAGONIST;

ADULT; ARTICLE; DRUG RECEPTOR BINDING; DRUG SCREENING; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOSIS; RECEPTOR AFFINITY;

ADULT; AMOXAPINE; BRAIN; FEMALE; HUMANS; MALE; PSYCHOTIC DISORDERS; RECEPTORS, DOPAMINE D2; RECEPTORS, SEROTONIN; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0033135453     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(98)00204-2     Document Type: Article

References (20)

1. Anton R.F. Jr, Burch E.A. Jr. Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression. Am J Psychiatry. 147:1990;1203-1208.
2. Anton R.F. Jr, Burch E.A. Jr. Response of psychotic depression subtypes to pharmacotherapy. J Affect Disord. 28:1993;125-131.
3. Blin J., Sette G., Fiorelli M., et al. A method for the in vivo investigation of the serotonergic 5-HT2 receptors in the human cerebral cortex using positron emission tomography and 18F-labeled setoperone. J Neurochem. 54:1990;1744-1754.
4. Bristow L.J., Kramer M.S., Kulagowski J., Patel S., Ragan C.I., Seabrook G.R. Schizophrenia and L-745, 870, a novel dopamine D4 receptor antagonist. Trends Pharmacol Sci. 18:1997;186-188.
5. Greenblatt E.N., Lippa A.S., Osterberg A.C. The neuropharmacological actions of amoxapine. Arch Int Pharmacodyn Ther. 233:1978;107-135.
6. Kapur S. A new framework for investigating antipsychotic action in humans Lessons from PET imaging . Mol Psychiatry. 3:1998;135-140.
7. Kapur S., Remington G., Zipursky R.B., Wilson A.A., Houle S. The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms A PET study . Life Sci. 57:1995;L103-PL107.
8. Kapur S., Zipursky R., Remington G., Jones C., McKay G., Houle S. PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors Implications for the therapeutics of schizophrenia . Am J Psychiatry. 154:1997;1525-1529.
9. Kapur S., Zipursky R., Remington G., et al. The 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia A PET investigation . Am J Psychiatry. 155:1998;921-928.
10. Lingjaerde O., Ahlfors U.G., Bech P., Dencker S.J., Elgen K. The UKU side effect rating scale A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients . Acta Psychiatr Scand Suppl. 334:1987;1-100.
11. Lydiard R.B., Gelenberg A.J. Amoxapine - An antidepressant with some neuroleptic properties? A review of its chemistry, animal pharmacology and toxicology, human pharmacology, and clinical efficacy. Pharmacotherapy. 1:1981;163-178.
12. Marder S.R., Meibach R.C. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 151:1994;825-835.
13. Meltzer H.Y. The role of serotonin in schizophrenia and the place of serotonin-dopamine antagonist antipsychotics. J Clin Psychopharmacol. 15:1995;2S-3S.
14. Meltzer H.Y., Matsubara S., Lee J.C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin-2 pKi values. J Pharmacol Exp Ther. 251:1989;238-246.
15. Midha K.K., Hubbard J.W., McKay G., Hawes E.M., Hsia D. The role of metabolites in a bioequivalence study Loxapine, 7-hydroxyloxapine and 8-hydroxyloxapine . Int J Clin Pharmacol Ther Toxicol. 31:1993;177-183.
16. Moore N.A., Tye N.C., Axton M.S., Risius F.C. The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. J Pharmacol Exp Ther. 262:1992;545-551.
17. 2 receptor occupancy in relation to clozapine serum concentration A PET study of schizophrenic patients . Am J Psychiatry. 152:1995;1444-1449.
18. Seeman P., Corbett R., VanTol H.H.M. Atypical neuroleptics have low affinity for dopamine D-2 receptors or are selective for D-4 receptors. Neuropsychopharmacology. 16:1997;93-110.
19. Simpson G.M., Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 212:1970;11-19.
20. Tollefson G.D., Beasley C.M. Jr, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders Results of an international collaborative trial . Am J Psychiatry. 154:1997;457-465.